112 results about "Lipoprotein cholesterol" patented technology

Relating to the technical field of gene therapy, provided is an siRNA molecule for inhibiting PCSK9 expression, and use thereof. Particularly, an siRNA molecule for inhibiting PCSK9 expression (comprising a sense strand and an anti-sense strand that are complementary to form a double-stranded region) and a pharmaceutical composition comprising the same are disclosed. The siRNA molecule has a high silencing efficiency and a long-lasting silencing effect for PCSK9 gene, and is useful in the manufacture of products for inhibiting PCSK9 protein expression, products for reducing the concentration of low-density lipoprotein or low-density lipoprotein cholesterol in serum; and products for relieving the symptoms of PCSK9 gene-mediated diseases.

The invention relates to the technical field of microorganisms, in particular to enterococcus faecalis EF-1 capable of reducing blood lipid, a microbial preparation and application of the enterococcus faecalis EF-1. The enterococcus faecalis EF-1 is preserved in the China General Microbiological Culture Collection Center (CGMCC) on September 27, 2024, and the preservation number is CGMCC No.32097. The enterococcus faecalis EF-1 is named as enterococcus faecalis EF-1. The enterococcus faecalis EF-1 has the functions of: (1) relieving the weight increase speed of animals, reducing body weight gain, and preventing, relieving or treating obesity; (2) the contents of triglyceride, cholesterol and low-density lipoprotein cholesterol in liver and serum are reduced; (3) the liver function is protected, and the contents of ALT and AST in serum and liver are reduced; (4) liver lipid deposition and lesion are relieved; (5) relieving adipose tissue hypertrophy; (6) preventing, relieving or treating metabolic syndrome; (7) reducing blood sugar, improving insulin resistance and relieving diabetes mellitus; 8, increasing the content of short-chain fatty acid; and (9) regulating intestinal flora.

The invention discloses lactobacillus plantarum YBE2 and application thereof.According to the lactobacillus plantarum YBE2 for high yield of extracellular polysaccharide mainly containing rhamnose, different cholate types can be degraded at the same time, glycocholic acid is specifically hydrolyzed, and the lactobacillus plantarum YBE2 has the effects of lowering cholesterol and relieving acute inflammation at the same time. Meanwhile, the plant lactobacillus YBE2 can reduce the deposition of fat in the belly of the cage rearing broiler chicken, improve intramuscular fat, promote the deposition of fatty acid in muscles, reduce the total bile acid of plasma, triglyceride and low-density lipoprotein cholesterol, and remarkably improve the lipid metabolism and muscle quality of meat poultry, and can be widely applied to the breeding of the cage rearing broiler chicken, promote the healthy breeding of the meat poultry and improve the quality of the meat poultry. The culture benefit is improved.

The invention provides novel application and a method of asiaticoside. The method comprises the following steps: S1, extraction: taking a centella asiatica medicinal material, performing coarse crushing, adding ethanol, performing reflux extraction, performing filtration, and combining filtrate for standby application; s2, concentrating: concentrating the ethanol extracting solution under reduced pressure until no alcohol smell exists, centrifuging, and reserving supernate for later use; s3, carrying out D101 column chromatography; s4, alumina column chromatography; s5, performing concentration; s6, drying; s7, dissolving with methanol, adding water, standing, and monitoring clear liquid and crystallization conditions in a liquid phase; s8, filtering after crystallization is finished, washing with ethanol, drying crystals under the conditions that the vacuum degree is-0.06 to-0.08 mpa and the temperature is 60-70 DEG C, and crushing and sieving dry paste to obtain asiaticoside; specifically, the new application comprises reduction of uric acid (UA), urea (UREA), creatinine (CREZ), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) and total cholesterol (CHOL) in serum of a hyperuricemia model SD rat, and reduction of damage of hyperuricemia to kidney. And the yield of asiaticoside extracted by the method is high and is about 84%.

The invention discloses a polysaccharide composition for treating hyperlipemia and application thereof, and belongs to the field of biological medicine. The polysaccharide composition is obtained by mixing phellinus linteus linteus, inonotus hispidus and boletus coratus and then performing water extraction. The polysaccharide composition provided by the invention can be used for reducing fat vacuolation and fat index, reducing the content of triglyceride, total cholesterol and low-density lipoprotein cholesterol in serum and increasing the content of high-density lipoprotein cholesterol by inhibiting the increase of weight and blood sugar of a hyperlipidemia mouse; the composition and abundance of intestinal flora are regulated and controlled, the intestinal flora disorder phenomenon is improved, the effect is better than that of single polysaccharide, and a new direction is provided for treatment for assisting blood sugar reduction.

The invention belongs to the technical field of natural medicines, and particularly discloses a lipase inhibitor with a specific structure as well as a preparation method and application thereof, the inhibitor is derived from grape leaves and contains C6-C3-C6, 1, 2-benzopyrone, diphenyl ethylene and a phenolic hydroxyl structure, and the lipase inhibitor is a lipase inhibitor with a specific structure. Comprising the following components in percentage by mass: 72.1 to 97.5 percent of flavonoids, 2.5 to 5.1 percent of coumarins, 2.0 to 3.2 percent of stilbenes and 5.1 to 8.3 percent of phenolic acids. According to the lipase inhibitor with the specific structure as well as the preparation method and the application of the lipase inhibitor, the inhibitor can inhibit secretion of lipase, prevent fat from being decomposed into absorbable free fatty acid and monoacylglycerol, and reduce fat absorption; the total cholesterol and the low-density lipoprotein cholesterol are reduced, the blood fat level is improved, and the composition can be applied to preparation of health-care products, functional foods, sports nutritious foods and formula foods for special medical purposes.

The invention relates to N-fluorenylmethoxycarbonyl-L-2-amino-5-phenylpentanoic acid or a pharmaceutical composition and application thereof, and relates to the technical field of biological medicines. According to the application disclosed by the invention, the N-fluorenylmethoxycarbonyl-L-2-amino-5-phenylpentanoic acid is found to have the effects of reducing total cholesterol, triglyceride and low-density lipoprotein cholesterol in serum and increasing high-density lipoprotein cholesterol in serum for the first time; the compound can be used for preparing a medicine for reducing total cholesterol in serum, a medicine for reducing triglyceride in serum, a medicine for reducing low-density lipoprotein cholesterol in serum and a medicine for increasing high-density lipoprotein cholesterol in serum, and can be used for preparing medicines for reducing total cholesterol in serum, triglyceride in serum, low-density lipoprotein cholesterol in serum and high-density lipoprotein cholesterol in serum. And an effective new means and a new way are provided for preparing the medicine for preventing or treating the hyperlipemia.

The invention relates to an shRNA (short hairpin Ribonucleic Acid) interference sequence of a targeted silence PCSK9 gene and a construction method and lipid-lowering application of a recombinant adeno-associated virus vector of the shRNA interference sequence. Hyperlipidaemia is a metabolic disease characterized by abnormal rising of cholesterol and triglyceride levels in blood, and the design of lipid-lowering drugs is the focus of attention to improvement of hyperlipidaemia. Proprotein convertase subtilisin / kexin type 9 (PCSK9) can be combined with a low-density lipoprotein receptor (LDL-R) and degrade the LDL-R, so that accumulation of LDL-C in blood is further promoted, and hyperlipidemia is caused. Aiming at the key target PCSK9, a specific shRNA interference sequence is designed, and a recombinant adeno-associated virus vector (rAAV) carrying the sequence is constructed by an enzyme digestion-connection method. In-vitro experiments prove that the vector can remarkably reduce the expression level of PCSK9 protein, so that the cyclic utilization of a low-density lipoprotein receptor (LDL-R) is promoted, and the concentration of low-density lipoprotein cholesterol (LDL-C) in plasma is reduced. The rAAV vector provided by the invention has the characteristics of low production cost, high transfection efficiency, lasting action time and the like, and provides a new thought for gene therapy of hyperlipidemia.

The invention relates to the technical field of biological medicine, in particular to application of cyclic dipeptide to improvement or treatment of dyslipidemia related diseases. According to the present invention, the research results show that the cyclo (glycerol-casein) dipeptide has good safety and cholesterol lowering activity, and can reduce mouse serum total cholesterol, low density lipoprotein cholesterol, increase serum high density lipoprotein cholesterol, reduce the content of liver total cholesterol, reduce liver fat accumulation, and slow down the weight increase of mice. The cyclic (glycerol-casein) dipeptide can realize the effect of lowering cholesterol by regulating intestinal flora. The cyclic (glycerol-tyrosine) dipeptide is derived from probiotics, food and medicines, belongs to food-borne cyclic dipeptide, and is high in safety and small in toxic and side effects. The cyclo (glycerol-casein) dipeptide is expected to be developed into a class of innovative medicines and health-care foods with the effect of reducing cholesterol, and has a very good application prospect. The invention also provides the cyclic (sweet-tyrosine) dipeptide and a health food and a pharmaceutical composition containing the cyclic (sweet-tyrosine) dipeptide.

The invention belongs to the technical field of functional microorganisms, and provides pediococcus acidilactici MR21 and application thereof. The pediococcus acidilactici MR21 provided by the invention is preserved in the China General Microbiological Culture Collection Center (CGMCC) on December 3, 2024, and the preservation number is CGMCC NO. 32896. The pediococcus acidilactici MR21 disclosed by the invention has efficient in-vitro cholesterol removal capacity, excellent safety and remarkable probiotic characteristics, and has the effects of restoring liver functions, reducing liver fat accumulation and regulating expression of fat and cholesterol metabolism related genes by remarkably reducing the content of serum total cholesterol and low-density lipoprotein cholesterol. Therefore, the function of relieving hypercholesterolemia is achieved.

The invention relates to the technical field of health care products, and provides a glycopeptide composition and related products and application thereof, and the glycopeptide composition comprises the following raw materials: wheat germs, herba epimedii, fermented bean products, flaxseeds and radix bupleuri. The glycoside peptide composition formed by combining the raw materials has a synergistic effect in the aspect of cardiovascular system protection. All the components interact with one another to jointly achieve the effects of reducing serum total cholesterol and triglyceride, improving high-density lipoprotein cholesterol, resisting oxidation, improving vascular functions and the like, and the composition has a remarkable protection effect on a cardiovascular system. Besides, the activity is enriched into the five raw materials to the maximum extent, so that the method has remarkable advantages in the aspects of production process and raw material cost reduction, and is beneficial to improving the production efficiency, ensuring the product quality and reducing the operation cost.

This invention discloses a low-astringency prickly pear lactic acid bacteria fermented beverage and its application in lowering blood lipids and antioxidation, relating to the fields of microbial application and food fermentation technology. The fermented beverage of this invention uses prickly pear juice as raw material and is prepared by fermentation with *Lactobacillus plantarum* R-21. It can significantly reduce the tannin content of prickly pear juice, improve taste, and increase the polysaccharide content and antioxidant properties of the beverage. In vivo experiments show that it can reduce the levels of triglycerides, total cholesterol, and low-density lipoprotein cholesterol in mouse liver and serum, inhibit fat accumulation and fatty degeneration in liver cells, and enhance the activity of antioxidant enzymes in the liver, demonstrating important application value in lowering blood lipids and antioxidation.

The invention relates to application of an asparagine endopeptidase inhibitor in preparation of a medicine for improving insulin resistance. According to the application, starting from inhibiting the aging driving factor AEP, the AEP inhibitor is tried to be applied to the research of insulin resistance for the first time, and the AEP inhibitor is found to be capable of remarkably improving glucose tolerance and insulin sensitivity. Therefore, the invention provides the application of the asparagine endopeptidase inhibitor in preparation of the medicine for improving insulin resistance. Experiments prove that the AEP inhibitor not only can significantly enhance insulin sensitivity of old mice and improve glucose tolerance, but also can reduce serum low-density lipoprotein cholesterol and lactic dehydrogenase levels, shows multiple improvement effects on glucose metabolism and lipid metabolism, and also can be used for preparing the AEP inhibitor. After long-term administration, obvious toxic and side effects are not found in pathological examinations of blood routine examination, urine routine examination, heart, liver, spleen, lung, kidney and other important organs, so that the traditional Chinese medicine composition is proved to have good safety and is suitable for long-term intervention of chronic diseases.

The present invention relates to use of a GLP-1R / GLP-2R dual agonist, namely dapiglutide, for reducing cholesterol, in particular total cholesterol (TC) and low-density lipoprotein cholesterol (LDL cholesterol). The invention also relates to dapiglutide for treatment of hyperlipidaemia, in particular hypercholesterolaemia.

The invention discloses application of a group of blood nutrition markers in prediction of central nervous system (CNS) injury function prognosis. According to the technical scheme, the method is characterized in that serum albumin, total cholesterol (TC) and low density lipoprotein cholesterol (LDL-C) are determined as independent predictive factors of CNS injury prognosis for the first time through retrospective queue research (n = 404), and clinical decision critical values are determined to be 36.35 g / L, 3.60 mmol / L and 2.13 mmol / L respectively. The detection kit developed on the basis of the discovery can objectively and quantitatively evaluate the prognosis risk of the patient within 24 hours of admission, and is obviously superior to that of a traditional scoring system. According to the method, key technical support is provided for precise nutrition intervention and early rehabilitation strategy formulation of the CNS injury.

The invention belongs to the technical field of functional compositions, and discloses a composition for dispelling effects of alcohol and protecting liver as well as a preparation method and application thereof, and the composition comprises the following raw materials in percentage by mass: 13-28% of ginseng, 18-28% of globe artichoke, 10-27% of pueraria peptide, 7-12% of houttuynia cordata, 7-9% of mulberry, 6-9% of gardenia and 10-29% of collagen composite peptide. The composition can reduce alcohol irritation, relieve alcohol absorption and increase the alcohol content; meanwhile, the liver and stomach are protected; meanwhile, alcohol metabolism is rapid, hangover is prevented, headache, dizziness, nausea and other uncomfortable symptoms caused by alcohol are relieved, and the drunkenness degree is relieved. After the medicine is taken for 2-6 months, mild fatty liver and moderate fatty liver can be obviously improved, and severe fatty liver and alcoholic liver can be obviously improved; indexes related to endocrine metabolism, such as blood sugar, blood fat, uric acid, triglyceride, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, glutamic oxalacetic transaminase and glutamic-pyruvic transaminase, are obviously improved.

The disclosure provides methods of treating heterozygous familial hypercholesterolemia (HeFH) and / or atherosclerotic cardiovascular disease (ASCVD), more particularly in subjects who require additional lowering of low-density lipoprotein cholesterol (LDL-C). The method comprises administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising obicetrapib or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

The invention discloses a preparation method of torreya grandis gel candies with an effect of reducing total cholesterol. The invention belongs to the technical field of functional food, the Chinese torreya oil and the flaxseed oil have a synergistic effect, and after the Chinese torreya oil and the flaxseed oil are compounded, the blood fat metabolism can be effectively regulated, the total cholesterol level can be reduced, and the content of high-density lipoprotein cholesterol can be increased; the Chinese torreya oil is extracted through a low-temperature pressing process, the linseed oil is prepared through a cold pressing process, active components in the raw materials are reserved to the maximum extent, and meanwhile, the stability and uniformity of functional components in the product are ensured by combining a feeding pump filtering process and a rolling die shaping process; by optimizing the formula and the preparation process of the gel matrix, the product has good elasticity and chewing feeling, is convenient to carry and take and is suitable for daily use. The health-care food does not contain artificially synthesized additives, all the raw materials are natural sources, and the health-care food is suitable for patients with hypercholesterolemia and crowds needing to regulate blood fat, and has relatively high safety and market promotion value.

The invention discloses a lactobacillus paracasei LP007 probiotic liquid with a blood fat reducing effect and a preparation method of the lactobacillus paracasei LP007 probiotic liquid. On the basis of the casei paracasei LP007 and in combination with functional components such as the red yeast rice extract, the gamma-aminobutyric acid and the DHA, the probiotic liquid with the remarkable blood fat reducing effect is successfully prepared. Experiments show that the probiotic liquid can effectively reduce serum total cholesterol, low-density lipoprotein cholesterol and triglyceride, improve the level of high-density lipoprotein cholesterol and optimize lipid metabolism, and in addition, the formula can also improve intestinal flora balance, enhance the antioxidant capacity of the body, protect the liver to a certain extent, reduce fatty degeneration and improve the immunity of the human body. Compared with a contrast group without red yeast rice and GABA, the probiotic liquid has remarkable advantages in lipid-lowering effect, has good taste and biological stability, and is suitable for being drunk for a long time as a functional health product.

This invention discloses a *Lactobacillus plantarum* YBE2 and its applications. The *Lactobacillus plantarum* provided by this invention, which produces a high amount of extracellular polysaccharides primarily composed of rhamnose, can simultaneously degrade different types of bile salts, including specifically hydrolyzing glycocholic acid. It also exhibits cholesterol-lowering and acute inflammation-relieving effects. Furthermore, *Lactobacillus plantarum* YBE2 can reduce fat deposition in the abdomen of caged broilers, increase intramuscular fat, promote fatty acid deposition in muscles, and reduce plasma total bile acids, triglycerides, and low-density lipoprotein cholesterol. This significantly improves lipid metabolism and muscle quality in poultry, and can be widely applied in caged broiler farming to promote healthy poultry farming and improve farming efficiency.

The invention relates to a quality control liquid for low-density lipoprotein cholesterol and a preparation method of the quality control liquid. The quality control liquid comprises the following components in percentage by weight: 90-95% of defatted bovine serum, 0.005-0.05% of a cholesterol solution purified by ultracentrifugation, 1-3% of trehalose, 0.2-0.4% of EDTA-2K, 0.02-0.05% of vitamin E, 0.08-0.12% of a liquid biological preservative and 0.1-0.2% of glutathione. The invention has the following beneficial effects: 1, trehalose and vitamin E have a synergistic effect, and the stability at normal temperature reaches more than 12 months (CV is less than 3%); 2, a direct detection method, a precipitation method and a calculation method are adapted, and the deviation with a clinical sample is less than 5%; 3, the synthetic matrix reduces the risk of biogenic pollution, and is suitable for an automatic detection platform.

The invention discloses a roxburgh rose lactic acid bacteria solid beverage and application thereof in preparation of foods, health-care products or medicines for reducing hyperlipidemia, preventing colitis and resisting oxidation, and belongs to the field of probiotic health-care foods. The rosa roxburghii tratt lactic acid bacteria solid beverage is prepared from plant lactobacillus R-15, rosa roxburghii tratt fine powder, mannan oligosaccharide, resistant dextrin, coix lacryma-jobi extract, hawthorn extract, silicon dioxide and the like. The rosa roxburghii tratt lactobacillus solid beverage can significantly reduce the levels of triglyceride, total cholesterol and low-density lipoprotein cholesterol in the liver and serum of a mouse, inhibit fatty degeneration of the liver, and inhibit colitis induced by high fat diet. The invention has important application value in prevention and treatment of hyperlipidemia and colitis.

This invention relates to a traditional Chinese medicine composition, specifically a traditional Chinese medicine composition for treating diabetic nephropathy, belonging to the fields of medicine and health products. The traditional Chinese medicine composition of this invention is made from components comprising the following raw materials: yam, salvia miltiorrhiza, rosehip, turtle shell, cornus officinalis, dioscorea hypoglauca, cuscuta chinensis, oyster shell, and American ginseng. Through rational formulation, this traditional Chinese medicine composition utilizes the principle of clearing heat and removing dampness, with the synergistic effect of multiple drugs, to significantly reduce fasting blood glucose, improve glucose metabolism, lower low-density lipoprotein cholesterol and triglycerides, and raise high-density lipoprotein cholesterol to regulate lipid metabolism, reduce weight, and has no significant damage to liver and kidney function, with minimal side effects.

The application belongs to the technical field of biological medicine, and provides application of THADA in hyperlipidemia and cardiovascular metabolic diseases. THADA is used as a biomarker or target to prepare reagents for disease prediction, screening or diagnosis, and to prepare drugs for preventing or treating diseases. Inhibition or destruction of THADA function has the purposes of reducing blood cholesterol, low-density lipoprotein cholesterol (LDL-C) and triglyceride levels, not affecting high-density cholesterol levels, reducing liver triglyceride deposition and liver steatosis, and improving atherosclerosis, and the effect is clear and effective and has no adverse reactions. The application provides a new biomarker and treatment target for hyperlipidemia and cardiovascular metabolic diseases, and has good practical application value and wide application prospect.

The present invention discloses the application of a Lactobacillus gasseri strain derived from breast milk in weight loss, blood lipid reduction, prevention and treatment of type 2 diabetes, alleviation of intestinal leakage and inhibition of intestinal pathogenic bacteria, belonging to the fields of microbial technology and pharmaceutical technology. The present invention provides a new use of Lactobacillus gasseri in weight loss, blood lipid reduction, prevention and treatment of type 2 diabetes, alleviation of intestinal leakage and inhibition of intestinal pathogenic bacteria, which can effectively reduce the prevention of weight gain, increase in body fat percentage, elevation of low-density lipoprotein cholesterol and triglycerides, inhibition of postprandial blood glucose and insulin resistance index elevation, inhibition of intestinal mucosal damage and growth of intestinal pathogenic bacteria caused by high-fat diet, and effectively improve the occurrence of chronic diseases in high-fat diet-fed mice. Therefore, Lactobacillus gasseri FN136 has great application prospects in the preparation of products for weight loss, blood lipid reduction, prevention and treatment of type 2 diabetes, alleviation of intestinal leakage and inhibition of intestinal pathogenic bacteria.

The invention relates to the field of intelligent medical treatment, in particular to a pregnancy disease risk prediction method and device based on biochemical indexes and a program product. Comprising the following steps: S1, acquiring serum biochemical index data of a pregnant woman; s2, comparing the serum biochemical indexes with a preset threshold value; the serum biochemical indexes include aspartate aminotransferase, total protein, albumin, lactic dehydrogenase, alkaline phosphatase, total bile acid, creatine kinase, blood sugar, urea nitrogen, uric acid, creatinine, glomerular filtration rate, potassium, chlorine, total calcium, serum magnesium, inorganic phosphorus, total cholesterol, triglyceride, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol and homocysteine. When one or more of the myoglobin, the hypersensitive troponin I, the prealbumin, the cystatin C and the creatine kinase isoenzyme MB are abnormal, judging that the pregnancy eclampsia exists. The method is simple, convenient and rapid to operate and low in cost, can be clinically popularized to predict the health state of the pregnant woman on a large scale, and has good clinical value.

The present invention discloses the preparation of Sipunculus nudus hypoglycemic peptide and its application in the preparation of drugs for regulating blood glucose and blood lipids in type 2 diabetes, belonging to the field of biomedical technology. The Sipunculus nudus polypeptide provided by the present invention can significantly reduce the blood glucose concentration of T2DM, regulate the level of insulin resistance, inhibit the levels of triglyceride and low-density lipoprotein cholesterol in the serum of T2DM, increase the level of high-density lipoprotein cholesterol, and at the same time has a protective effect on the pathological changes of pancreatic tissue. In addition, administration of Sipunculus nudus polypeptide can increase the activity of SOD in the serum and inhibit the expression of malondialdehyde, a lipid peroxidation marker. The Sipunculus nudus polypeptide can significantly improve the abnormal blood glucose and blood lipids in type 2 diabetes, and has no toxicity or side effects on animals and will not accumulate in animals. Therefore, the Sipunculus nudus polypeptide can be used to prepare drugs or foods for regulating blood glucose and blood lipids in type 2 diabetes.

A method that enables quantification of cholesterol in high-density lipoprotein 3 (HDL3) in a test sample without requiring a laborious operation is disclosed. The method for quantifying cholesterol in HDL3 comprises: Step 1 wherein phospholipase and / or sphingomyelinase is / are allowed to act on a test sample to transfer cholesterol to the outside of the reaction system; and Step 2 wherein cholesterol remaining in the reaction system is quantified. The method enables specific quantification of HDL3 cholesterol in a test sample using an automatic analyzer without requirement of a laborious operation such as ultracentrifugation or pretreatment. Further, quantification of the HDL2 cholesterol level can also be carried out by subtracting the HDL3 cholesterol level from the total HDL cholesterol level obtained by a conventional method for quantifying the total HDL cholesterol in a test sample.

According to the human body metabolic system physiological age prediction method based on machine learning, six blood detection indexes including total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, blood sugar, glycosylated hemoglobin and triglyceride which are closely related to a metabolic system are collected in a targeted manner; and respectively carrying out computer model modeling on male and female data according to the physical examination data of the metabolic system, and constructing a computer model for predicting the physiological age of the human metabolic system of the male and female so as to evaluate the physiological age of the human metabolic system of individuals with different genders. According to the human body metabolism system physiological age prediction method based on machine learning, core data only uses blood data indexes related to the human body metabolism system for modeling, the physiological age model of the human body metabolism system is constructed, and the physiological age of the human body metabolism system can be evaluated in a targeted mode; modeling is carried out for men and women based on data differences of genders of men and women, so that the prediction result is more accurate.

The invention discloses compound oil with functions of regulating blood fat and relaxing bowel as well as a preparation method and application of the compound oil. The invention aims at solving the health problems of human body hyperlipidemia, constipation and the like. The preparation method of the compound oil with the functions of regulating blood fat and relaxing bowel comprises the following steps: 1, respectively filtering the krill oil and the cannabis oil at low temperature to remove impurities, and mixing the filtered krill oil and cannabis oil according to the mass ratio of (10-90): (90-10); dissolving and uniformly dispersing astaxanthin by using an organic solvent to obtain an astaxanthin solution; 2, uniformly stirring and mixing the filtered krill oil and cannabis oil with the astaxanthin solution at the temperature of 40-50 DEG C; the compound oil disclosed by the invention can regulate blood fat and relax bowel, wherein the blood fat regulation is embodied by reducing the levels of cholesterol and triglyceride and increasing the level of high-density lipoprotein cholesterol; intestine moistening and bowel relaxing are embodied in improving intestinal functions, enhancing intestinal peristalsis, relieving constipation and maintaining intestinal microecological balance.